Dover Advisors’s Novo Nordisk NVO Stock Holding History

Dover Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,850	Closed	-$335K	–	172
2025 Q2	$335K	Sell	4,850 -2,304	-32%	-$157K	0.15%	122
2025 Q1	$505K	Buy	+7,154	New	+$591K	0.22%	97

Other funds holding NVO

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dover Advisors's NVO Position: Q3 2025 in Review

Dover Advisors sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 4,850 shares — an estimated $335K sold.

Dover Advisors first reported a position in NVO in Q1 2025 and held it in 2 quarters. The position peaked at $505K in Q1 2025. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

Dover Advisors reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
Dover Advisors sold 4,850 Novo Nordisk shares in Q3 2025, an estimated $335K.
Dover Advisors first reported a position in Novo Nordisk in Q1 2025 and held it in 2 quarters.
Dover Advisors's Novo Nordisk position peaked at $505K in Q1 2025.
1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Dover Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.